September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.

Lymphoma diagnosis: an update.

Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623–32. 24 Bokemeyer C, Aapro MS, Courdi A et al; European Organisation for Research and Treatment of Cancer (EORTC). Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Review. Eur J Cancer 2007;43:258–70. 25 Rizzo J...

An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology.

Disclosures: Matti Aapro: Consultant/advisory role: ESMO, SIOG, ESO, EuroCancer, EORTC, IUCC; Honoraria: Amgen, Johnson & Johnson, Roche, Sanofi-Aventis, Bayer Schering, Merck-Serono, Merck, Helsinn, Novartis, Pfizer, Pierre Fabre; Research funding/contracted research: Amgen, Roche, Sanofi-Aventis, Merck-Serono, Merck, Helsinn, Cephalon, Pierre Fabre. The content of this article has been review...

Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update.

Canadian supportive care recommendations for the management of anemia in patients with cancer

Anemia is a common finding in cancer patients, most often as a result of chemotherapy. Management of anemia requires a comprehensive approach of appropriate diagnosis, exclusion of reversible causes, use of erythropoiesis-stimulating agents (ESAS), and iron supplementation. Recently, consensus guidelines on the management of chemotherapy-induced anemia were published in Europe and the United St...

Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study

Intravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of age admitted to University Health System Hospitals with a primary or secondary diagnosis of CKD between January 1, 2006 to December 31, 2008. A clust...